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OBJECTIVE — Usingtheclamptechnique,youthswithaclinicaldiagnosisoftype2diabetes
(CDx-type 2 diabetes) and positive pancreatic autoantibodies (Ab
) were shown to have severe
impairment in insulin secretion and less insulin resistance than their peers with negative anti-
bodies (Ab
). In this study, we investigated whether oral glucose tolerance test (OGTT)-derived
indexes of insulin secretion and sensitivity could distinguish between these two groups.
RESEARCH DESIGN AND METHODS — A total of 25 Ab
,1 1A b
 CDx-type 2
diabetic, and 21 obese control youths had an OGTT. Fasting and OGTT-derived indexes of
insulin sensitivity (including the Matsuda index, homeostasis model assessment [HOMA] of in-
sulin resistance, quantitative insulin sensitivity check index, and glucose-to-insulin ratio) and
insulin secretion (HOMA of insulin secretion and 30-min insulogenic and C-peptide indexes)
were used. Glucagon and glucagon-like peptide (GLP)-1 responses were assessed.
RESULTS — Fasting C-peptide and C-peptide–to–glucose ratio, and C-peptide area under
thecurve(AUC)weresigniﬁcantlylowerintheAb
CDx-type2diabeticpatients.OtherOGTT-
derivedsurrogateindexesofinsulinsensitivityandsecretionwerenotdifferentbetweentheAb

versus Ab
 patients. GLP-1 during the OGTT was highest in the Ab
 youths compared with the
other two groups, but this difference disappeared after adjusting for BMI. Ab
 and Ab
 CDx-
type 2 diabetes had relative hyperglucagonemia compared with control subjects.
CONCLUSIONS — TheclinicalmeasuresoffastingandOGTT-derivedsurrogateindexesof
insulin sensitivity and secretion, except for fasting C-peptide and C-peptide AUC, are less
sensitive tools to distinguish metabolic/pathopysiological differences, detected by the clamp,
between Ab
 and Ab
 CDx-type 2 diabetic youths. This underscores the importance of using
moresensitivemethodsandtheimportanceofdeterminingantibodystatusinobeseyouthswith
CDx-type 2 diabetes.
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D
iabetes in youth is generally classi-
ﬁed into two major categories: type
1diabetescharacterizedbyautoim-
mune destruction of the pancreatic
-cells and absolute insulin deﬁciency
and type 2 diabetes characterized by in-
sulin resistance coupled with a nonim-
mune-mediated -cell failure and relative
insulin deﬁciency (1). While type 1 dia-
betes remains the most common form of
childhood diabetes, type 2 diabetes in
youth has increased worldwide over the
last decade concomitant with the epi-
demic increase in childhood obesity
(2,3). The diagnosis of type 1 versus type
2 diabetes in children relies largely on the
clinical presentation with obesity being a
major characteristic of children diag-
nosed with type 2 diabetes (1,2). How-
ever, the increasing prevalence of obesity
in children, including those newly diag-
nosed with type 1 diabetes, has made the
clinical distinction between the two types
of diabetes more difﬁcult (4). Moreover,
10–75% of physician-diagnosed obese
youth with type 2 diabetes have islet cell
autoantibodies (3,5–7), which is the hall-
markofautoimmunetype1diabetes.Ina
previous study using the hyperinsuline-
mic-euglycemic and the hyperglycemic
clamp, we demonstrated important dis-
tinguishing features in insulin sensitivity
and secretion between antibody-positive
(Ab
)versus-negative(Ab
)obeseyouth
withaclinicaldiagnosisoftype2diabetes
(CDx-type2diabetes).Whileinsulinsen-
sitivity was severely impaired in Ab
 but
not Ab
 patients, -cell function was al-
most completely abolished in Ab
 and
not Ab
 type 2 diabetes (8). Moreover,
the Ab
 CDx-type 2 diabetic patients had
features consistent with the metabolic
syndrome. These pathophysiological dif-
ferences have important bearing on the
managementofdiabetesandhighlightthe
importanceofmakingthecorrectdiagno-
sis. While the clamp technique is consid-
ered the gold standard for studying in
vivo insulin secretion and sensitivity, its
use is limited to the research setting.
Therefore, in this study, we investigated
whether the oral glucose tolerance test
(OGTT), a clinically applicable tool,
could be used to distinguish the differ-
ences in insulin sensitivity and secretion
between the two groups of patients with
phenotypic type 2 diabetes versus obese
control subjects with normal glucose
tolerance.
RESEARCH DESIGN AND
METHODS— Thirty-six obese ado-
lescents, all reported previously (8), with
CDx-type 2 diabetes diagnosis made by
the attending endocrinologist based on
the American Diabetes Association diag-
nosticcriteria(1),wererecruitedfromthe
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ofPittsburgh.Isletcellantibodyscreening
revealed 25 with negative antibodies and
11 with positive antibodies. Islet cell an-
tibodies were tested using the National
Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK)-sponsored
harmonization assay. The control group
consisted of 21 age-matched obese, oth-
erwise healthy, adolescents recruited
from the community. All study partici-
pants were pubertal. The treatment mo-
dalities at the time of the study and the
characteristicsofthestudypopulationare
summarizedinTable1.Noneoftheobese
controlsubjectswereonmedicationsthat
affectbloodglucosemetabolism.Allstud-
ies were approved by the University of
Pittsburgh Institutional Review Board,
and consents and assents were obtained
prior to the investigation.
Autoantibody testing
GAD 65 kDa autoantibody (GAD65 Ab)
and insulinoma-associated protein 2 au-
toantibody (IA2) were measured using a
standardized assay protocol and a com-
mon serum calibrator developed by the
NIDDK-sponsored standardization group.
Results are expressed as DKU/ml. Based
on analysis of 550 samples, the cutoff val-
ues for positivity/negativity are 33
DKU/ml for GAD65 and 5 DKU/ml for
IA2. The calculated assay speciﬁcity is 97
for GAD65 and 99 for IA2, while the sen-
sitivity is 76 and 64, respectively.
OGTT
Study participants were admitted to the
Pediatric Clinical and Translational Re-
search Center at the Children’s Hospital
of Pittsburgh. After a 10- to 12-h over-
night fast, they underwent a 2-h OGTT
(1.75 g/kg, maximum 75 g). Blood sam-
ples were obtained at 15, 0, 15, 30, 60,
90,and120minfordeterminationofglu-
cose, insulin, C-peptide, glucagon, and
GLP-1 levels. Metformin was discontin-
ued 36 h prior to the OGTT. Patients did
not receive long- or intermediate-acting
insulin for 24 h prior to the OGTT. The
last dose of short-acting insulin was given
6–8 h prior to the OGTT.
Biochemical measurements
Plasma glucose was measured with a glu-
cose analyzer (Yellow Springs Instru-
ment, Yellow Springs, OH). Insulin,
C-peptide, glucagon, leptin, and adi-
ponectin were measured using radioim-
munoassayasbefore(9).OneAb
patient
had high levels of nonspeciﬁc binding in
the insulin radioimmunoassay, and her
insulin data were not included in this
analysis. A1C was measured by high-
performance liquid chromatography
(Tosoh Medics) (9). GLP-1 was measured
in 22 CDx-type 2 diabetic and 14 control
subjects who had plasma samples col-
lectedintubescontainingdipeptidylpep-
tidase-4 inhibitor (Millipore, St. Charles,
MO). Serum GLP-1 was measured on the
Luminex 200 IS (Luminex, Austin, TX)
using a one-plex human endrocrine hor-
mone MILLIplex Kit (catalog no.
HENDO-65K-01; Millipore). This assay
speciﬁcally detects GLP-1 (7–36) amide
and GLP-1 (7–37), with no detectable
cross-reactivity with GLP-2, GLP-1 (9–
36), or glucagon. In our laboratory, the
inter- and intra-assay coefﬁcients of vari-
Table1—Participants’ demographics and fasting laboratory data
Clinically diagnosed type 2
diabetes Obese control
subjects ANOVA P
Post hoc P
(Ab
 vs. Ab
)* Ab
 Ab

n 25 11 21
Age (years) 15.1  0.4 14.0  0.7 14.5  0.3 0.23 0.3
Sex (male/female)† 12/13 5/6 8/13 0.79†
Ethnicity (African American/white)† 13/12 5/6 12/9 0.82†
Tanner (n)† 0.31†
II–III 2 3 3
IV–V 23 8 18
BMI (kg/m
2) 36.4  1.1 30.4  1.3 36.5  1.1 0.005 0.008
BMI (%) 98.8  0.2 96.5  1.2 98.7  0.4 0.008 0.01
BMI Z score 2.39  0.1 1.99  0.1 2.35  0.1 0.005 0.005
Waist circumference (cm) 108.6  2.8 92.4  3.6 104.2  2.8 0.006 0.004
Percent body fat (%) 41.2  1.4 39.6  2.5 44.3  1.0 0.1 1.0
Visceral adipose tissue (cm
2) 85.6  8.6 52.0  6.9 59.2  4.1 0.006 0.019
Subcutaneous abdominal adipose tissue (cm
2) 532.7  29.5 432.8  42.1 517.0  38.6 0.2 0.24
A1C (%) 6.7  0.2 6.3  0.3 5.4  0.1 0.001 0.78
Diabetes duration (months) 8.2  2.3 4.5  1.4 NA 0.3
Treatment modality n (%)† 0.069†
Lifestyle n (%) 7 (28) 2 (18) NA
Insulin 3 (12) 1 (9) NA
Metformin 10 (40) 1 (9) NA
Insulin and metformin 5 (20) 7 (64) NA
Proinsulin-to-insulin ratio 0.25  0.03 0.21  0.08 0.28  0.05 0.59 1.0
Leptin (ng/ml) 31.6  2.9 23.3  4.0 42.6  3.8 0.004 0.37
Adiponectin (g/ml) 5.2  0.6 7.1  1.6 6.3  0.4 0.25 0.34
Leptin-to-adiponectin ratio 8.9  1.6 4.1  0.9 7.9  1.3 0.13 0.14
Data are means  SE. *Post hoc Bonferroni correction for Ab
 versus Ab
 type 2 diabetic patients. †	
2 analysis. NA, not applicable.
Tfayli and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 3, MARCH 2010 633ation were 7.7 and 5.1%, respectively.
Proinsulin levels were determined at Eso-
terix (Calabasas Hills, CA).
Body composition
Body composition was determined by
dual-energy X-ray absorptiometry. Sub-
cutaneous abdominal adipose tissue and
visceral adipose tissue were examined by
asingle-slicecomputedtomography(CT)
scan at L4–L5 as described (8).
Calculations: OGTT-derived indexes
of insulin sensitivity
Compositewhole-bodyinsulinsensitivity
(WBISIMatsuda) index, the homeostasis
model assessment for insulin resistance
(HOMA-IR), the quantitative insulin sen-
sitivitycheckindex(QUICKI),theCeder-
holm (ISICederholm), the Stumvoll
(ISIStumvoll),theGutt(ISIGutt),andtheAv-
ignon (ISIAvignon) insulin sensitivity in-
dexes were calculated as per published
equations (10,11).
OGTT-derived indexes of insulin
secretion
Theinsulogenicindex(
I30/
G30),using
fasting and 30-min OGTT insulin or C-
peptide (
C-pep30/
G30), and the
HOMA of insulin secretion (HOMA-%)
were calculated as before (12,13). The
area under the curve (AUC) for glucose
and insulin were calculated using the
trapezoidal rule.
Statistical analysis
Comparison of continuous variables be-
tween the three groups (Ab
,A b
, and
control subjects) was performed using
univariate ANCOVA with post hoc Bon-
ferroni correction. A three-way repeated-
measures analysis was used to compare
glucose, insulin, C-peptide, glucagon,
and GLP-1 responses during the OGTT
among the three groups with time as a
factor. ANCOVA and repeated-measures
analyses were adjusted for BMI. Categor-
ical variables were compared using the 	
2
analysis. A P value of 0.05 was consid-
ered statistically signiﬁcant. All values are
reported as means  SE.
RESULTS
Study participants
Theclinicalandphysicalcharacteristicsof
the study participants are summarized in
Table 1. There were no signiﬁcant differ-
ences in age, sex, Tanner stage, and eth-
nicity among the groups. The Ab

patients had signiﬁcantly lower BMI, BMI
percentile, Z score, waist circumference,
andvisceraladiposetissuecomparedwith
their Ab
 peers and the obese control
subjects. A1C at the time of the study was
comparable between the Ab
 and the
Ab
 CDx-type 2 diabetic and higher than
obese control subjects. Diabetes duration
was similar between the two groups of
CDx-type 2 diabetic patients. More Ab

patients tended to be on metformin and
lifestyle intervention than Ab
 patients.
All subjects in the obese control group
had normal glucose tolerance as deﬁned
byWorldHealthOrganizationandAmer-
ican Diabetes Association criteria (1).
Fasting and OGTT glucose, insulin,
and C-peptide
Fasting glucose and insulin were not sig-
niﬁcantlydifferentbetweenAb
andAb

patients (Table 2) (Fig. 1). However, fast-
ing C-peptide was lower in Ab
 versus
Ab
 patients (Table 2). Glucose, insulin,
and C-peptide responses during the
OGTT after adjusting for BMI in the three
groups are summarized in Fig. 1A–C.I na
three-way repeated-measures analysis
withtimeasafactorandBMIascovariate,
glucose levels during the OGTT were sig-
niﬁcantly different among the three
groups (P  0.001) and were highest in
Ab
 versus Ab
 (P  0.003) and lowest
in control subects (P  0.001). Insulin
levels were signiﬁcantly different among
the three groups (P  0.006) and was
lowest in Ab
 and highest in control sub-
jects with no signiﬁcant difference be-
Table 2—Fasting and OGTT-derived surrogate indexes of insulin sensitivity and secretion in Ab
 vs. Ab
 clinically diagnosed type 2 diabetic
patients and obese control subjects
Clinically diagnosed type 2 diabetes Obese control
subjects ANCOVA P
Post hoc P
(Ab
 vs. Ab
)* Ab
 Ab

n 25 11 21
GF (mg/dl) 117.9  4.7 130.2  7.6 85.9  5.1 0.001 0.55
IF (U/ml) 47.1  4.6 34.3  7.6 25.5  4.9 0.008 0.5
C-PepF (ng/ml) 4.2  0.3 2.5  0.4 3.2  0.3 0.001 0.002
Fasting and OGTT-derived indexes
of insulin sensitivity
GF/IF (12) 3.2  0.4 4.5  0.7 4.8  0.5 0.05 0.4
HOMA-IR (10) 14.9  2.2 11.9  3.6 5.0  2.3 0.01 1.0
QUICKI (10) 0.274  0.004 0.282  0.006 0.307  0.004 0.001 0.95
WBISIMatsuda (10) 1.23  0.2 1.74  0.3 1.99  0.2 0.012 0.43
ISICederholm (10) 23.6  1.6 16.7  2.6 40.3  1.8 0.001 0.1
ISIGutt (10) 2.9  0.1 3.1  0.2 4.0  0.1 0.001 1.0
ISIStumvoll (10) 0.015  0.01 0.069  0.02 0.016  0.01 0.07 0.1
ISIAvignon (11) 0.33  0.06 0.39  0.09 0.67  0.06 0.001 1.0
Fasting and OGTT-derived indexes
of insulin secretion
C-PepF/G F 0.036  0.002 0.020  0.004 0.037  0.003 0.001 0.002
HOMA-% (12) 329.1  42.9 254.5  70.9 400.9  45.7 0.21 1.0

I30/
G30 1.13  0.5 0.79  0.9 5.0  0.6 0.001 1.0

C-Pep30/
 G30 0.06  0.01 0.02  0.02 0.16  0.01 0.001 0.44
Data are means adjusted for BMI  SE. *Post hoc Bonferroni correction for Ab
 versus Ab
 type 2 diabetic patients.
Antibody status, OGTT, and -cell function
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 and Ab
 patients. C-peptide
levels were signiﬁcantly different among
the three groups (P  0.001) and was
highest in Ab
 versus Ab
 (P  0.001),
withnosigniﬁcantdifferencebetweenthe
Ab
 patients and the obese control sub-
jects. Because glucose levels differed dur-
ing the OGTT among the three groups,
C-peptide levels relative to glucose levels
are depicted as the C-peptide–to–glucose
ratio Fig. 1D. C-peptide–to–glucose ratio
differed signiﬁcantly among the three
groups and was highest in control sub-
jectsandlowestinAb
patients,withsig-
niﬁcant differences between the Ab
 and
Ab
 patients (P  0.001). The glucose
AUCwashighestintheAb
patients(P
0.001) and signiﬁcantly higher than Ab

patients (P  0.001) (Fig. 1G). C-peptide
AUC was signiﬁcantly lower in the Ab

compared with the Ab
 patients and
Figure 1—A–F: Glucose, insulin, C-peptide, C-peptide–to–glucose ratio, GLP-1, and glucagon, respectively, during the OGTT in Ab
 CDx-type 2
diabetes (‚) versus Ab
 CDx-type 2 diabetic patients (Œ) versus obese control subjects (F). G–L: Area under the curve (AUC) for glucose, insulin,
C-peptide, C-peptide–to–glucose ratio, GLP-1, and glucagon relative to glucose, respectively, during the OGTT in Ab
 CDx-type 2 diabetes ( )
versus Ab
 CDx-type 2 diabetes (f) versus obese control subjects ( ). Data adjusted for BMI. *P  0.001 for Ab
 vs. Ab
 post hoc Bonferroni
correction.
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between the latter two. C-peptide AUC
relative to glucose AUC (Fig. 1J) was sig-
niﬁcantly different among the three
groups (0.016  0.007, 0.049  0.004,
and 0.074  0.004 ng/ml per mg/dl),
with signiﬁcant differences between Ab

and Ab
 patients (P  0.001).
Fasting and OGTT-derived indexes
of insulin sensitivity
Fasting glucose–to–insulin ratio, HOMA-
IR, WBISIMatsuda, QUICKI, ISICederholm,
ISIGutt, and ISIAvignon were signiﬁcantly
different among the three groups, while
ISIStumvollwasnot.Noneoftheseindexes,
however, were signiﬁcantly different be-
tween Ab
 and Ab
 CDx-type 2 diabetes
(Table 2).
Fasting and OGTT-derived indexes
of insulin secretion
Fasting C-peptide–to–glucose ratio, 30-
min insulinogenic index, 
I30/
G30,
and
C-Pep30/
G30 were signiﬁcantly
different among the three groups, but
HOMA-% was not. Fasting C-peptide–
to–glucose ratio was signiﬁcantly lower
in the Ab
 versus Ab
 patients with and
without adjustment for BMI, with no sig-
niﬁcant differences in HOMA-%, 
I30/

G30, and 
C-Pep30/
G30 (Table 2).
GLP-1 and glucagon responses
during the OGTT
A subset of participants (13 Ab
,9A b
,
and14obesecontrolsubjects)hadGLP-1
data.GLP-1responseandAUCduringthe
OGTT were signiﬁcantly different among
the three groups and highest in Ab
 pa-
tients (Fig. 1E and K). However, this dif-
ference disappeared after adjusting for
BMI (Fig. 1E).
The glucagon levels (Fig. 1F)a n d
AUC (7,233  587 vs. 6,150  590 and
5,366  713 pg   ml
1   min
1 in Ab
,
Ab
, and obese control subjects, respec-
tively; P  0.1) during the OGTT were
not different among the three groups.
However, when corrected for prevailing
glucose levels during the OGTT (gluca-
gon AUC  glucose AUC) the glucagon
levels were lowest in the control sub-
jects compared with the two groups of
diabetic subjects despite adjustment for
BMI (Fig. 1L).
Adiponectin, leptin, and proinsulin
Leptin was signiﬁcantly different among
the three groups and lowest in Ab
 pa-
tientsversusobesecontrolsubjectsbefore
(P  0.004) and after (P  0.03) adjust-
ing for BMI. Adiponectin, leptin-to-
adiponectin ratio, and proinsulin-to-
insulin ratio were not different among the
three groups (Table 1).
CONCLUSIONS— The childhood
obesity epidemic has resulted in increas-
ing numbers of youth presenting with
type 2 diabetes, but, in addition, type 1
diabetic children have become over-
weight/obese (1,4). This has made the
proper clinical distinction between obese
type 1 versus type 2 diabetes challenging,
especially when a signiﬁcant number of
physician diagnosed obese youth with
type 2 diabetes have circulating-cell au-
toantibodies (3,5–7). In the present
study, even though the Ab
 youth were
statistically signiﬁcantly less obese than
the Ab
 ones, from a clinical signiﬁcance
perspectivetheywerestillveryobese.Ina
previous publication using the state-of-
the-art methodology of the clamp, we re-
ported severe impairment in insulin
secretion in Ab
 subjects with CDx-type
2 diabetes in contrast to severe impair-
ment in insulin action in the Ab
 patients
(8).Thecurrentstudyinvestigatedwhether
theOGTT,aclinicallyapplicabletool,could
reveal differences in insulin secretion and
sensitivity in Ab
 versus Ab
 patients to
assistinthediagnosisofthetypeofdiabetes.
Our data show that fasting C-peptide, fast-
ing C-peptide–to–glucose ratio, and C-
peptide AUC during the OGTT are
signiﬁcantly lower in Ab
 versus Ab

CDx-type 2 diabetic youths, while none
of the other parameters are different. Par-
ticularly, none of the sensitivity indexes
could distinguish between Ab
 and Ab

CDx-type 2 diabetes.
In our previous study, using the hy-
perinsulinemic-euglycemic clamp, we
demonstrated that insulin sensitivity was
signiﬁcantly lower, 
45% in Ab
 versus
Ab
 patients (8). In the current 25 Ab

and 11 Ab
 patients, with the new DK
islet cell antibody harmonization assay,
thedataareconsistentwithpriorpublica-
tion. In vivo insulin sensitivity in Ab
 pa-
tients is lower than Ab
 patients (1.5 
0.2 vs. 3.1  0.4 mg   kg
1   min
1 per
U/ml;P0.001).However,noneofthe
eight different fasting and OGTT-derived
surrogate indexes of insulin sensitivity
(Table 2) revealed statistically signiﬁcant
differences between the two groups of
type 2 diabetic youths. This may not be
surprising since during the clamp, glu-
coseismaintainedateuglycemiainallpa-
tients, unlike the OGTT where glucose
levels are highly variable (Fig. 1A) and
dependent on endogenous insulin secre-
tion. The same is true for insulin levels,
which are highly variable during the
OGTT(Fig.1B)butcontrolledwithacon-
stant rate infusion of insulin during the
hyperinsulinemicclamp,resultinginsim-
ilar steady-state clamp insulin levels
among all patients. Similar to our current
ﬁndings, a study in adults using the
HOMA index reported similar insulin
sensitivity between patients with latent
autoimmune diabetes of adults (LADA)
and patients with GAD-negative type 2
diabetes of short duration (14). In con-
trast, data from the A Diabetes Outcomes
Progression Trial (ADOPT) showed sig-
niﬁcantly lower HOMA-IR in adult pa-
tients with GAD-positive type 2 diabetes
compared with GAD negative (15). This
ﬁnding, though consistent with our pre-
vious observation of better insulin sensi-
tivity in Ab
 youths, differs from our
currentﬁndings.Thisismostlikelydueto
the much larger cohort in the ADOPT,
which increases statistical power despite
using a less sensitive method than the
clamp. In addition, however, GAD-
positive patients had a lower BMI and
may therefore have been more insulin
sensitive (15). Another small study, using
the insulin-modiﬁed frequently sampl-
ed intravenous glucose tolerance test,
showed similar insulin sensitivity be-
tween eight GAD-negative and eight
GAD-positive adult patients with type 2
diabetes, matched for BMI and glycemic
control (16), consistent with our current
ﬁndings.
With regards to insulin secretion, us-
ing the hyperglycemic clamp previously
we demonstrated that ﬁrst- and second-
phase insulin secretion was signiﬁcantly
lower (
5 0 % )i nA b
 versus Ab
 pa-
tients (8). In the present 25 Ab
 and 11
Ab
 patients, ﬁrst-phase insulin and C-
peptide were signiﬁcantly different
(77.1  10.2 vs. 38.4  4.2 u/ml, P 
0.001; 5.7  0.4 vs. 2.4  0.3 ng/ml,
respectively; P  0.001). However, nei-
ther the 
I30/
G30 nor 
C-Pep30/
G30
were signiﬁcantly different between the
two groups of type 2 diabetic youths (Ta-
ble 2). This, again, may be due to the fact
that during the hyperglycemic clamp, the
insulin response is standardized to the
same glucose stimulus in all patients
(
225 mg/dl), while this is not the case
during the OGTT, where glucose levels
are highly variable. There are no prior
studies comparing insulin secretion dur-
ing the OGTT in Ab
 versus Ab
 young
CDx-type 2 diabetic patients. Studies
Antibody status, OGTT, and -cell function
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positive LADA showed that fasting and
stimulated C-peptide levels were reduced
compared with islet cell antibody–
negative type 2 diabetic patients (17),
consistent with our ﬁndings. Similarly
HOMA-% was not different between
Ab
 and Ab
 patients. In normal chil-
dren, the reported correlations of
HOMA-% with clamp-derived ﬁrst-
phase insulin secretion range between
0.54 and 0.82 depending on the pubertal
stage and glucose tolerance status
(13,18). Furthermore, HOMA-%, fast-
ing insulin, and fasting insulin/glucose
arereportednottoperformwellindetect-
ing differences in insulin secretion in ad-
olescentswithimpairedglucosetolerance
(13). Therefore, it is not surprising that
OGTT-derived indexes of insulin secre-
tion were not sensitive enough to detect
differences in insulin secretion between
Ab
 and Ab
 Cx-type 2 diabetes in the
current study.
Studies comparing Ab
 versus Ab

youngpatientswithphenotypictype2di-
abetes mostly explored the differences in
clinical characteristics at presentation
(3,5–7), and none evaluated the differ-
ences in metabolic responses during the
OGTT between the two groups. In the
current study, glucose AUC was signiﬁ-
cantly higher and C-Peptide AUC, per se,
orrelativetoprevailingglucoselevelswas
signiﬁcantly lower in Ab
 versus Ab
 di-
abeticyouth.Thisisconsistentwithapre-
liminary report from the multicenter
study Treatment Options for Type 2 Dia-
betes in Adolescents and Youth (TODAY)
that found a tendency for lower fasting
C-peptide levels in 48 Ab
 patients com-
pared with 357 Ab
 patients (7). In con-
trast,anotherstudyfromEuropereported
no differences in C-peptide or glucose
levelsatmanifestationbetweenagroupof
82Ab
andagroupof46Ab
youthwith
CDx-type 2 diabetes (6). Another study
from the U.S. did not ﬁnd signiﬁcant dif-
ferences in fasting C-peptide levels be-
tween 24 GAD-negative young type 2
diabetic patients compared with 24 obese
control subjects (5). The observation that
C-Peptide AUC/glucose AUC during the
OGTTissigniﬁcantlylowerinAb
versus
Ab
 patients may be a helpful metabolic
marker, besides the fasting C-peptide, to
distinguish Ab
 and Ab
 youths with
type 2 diabetes. Despite the lack of statis-
tical signiﬁcance in the differences in
treatment modalities between the Ab

and Ab
 patients in our current study;
treatment with metformin versus insulin
mayhaveaffectedtheinterpretationofthe
fasting and OGTT-derived indexes of in-
sulin secretion and sensitivity.
Relativehyperglucagonemiaisshown
in adults with type 2 diabetes and with
LADA who had higher glucagon concen-
trations and less suppression of glucagon
with hyperglycemia compared with con-
trol subjects (14). In the present study,
therewasevidenceofhyperglucagonemia
relativetotheprevailingglycemiainCDx-
type 2 diabetic patients compared with
controlsubjectsconsistentwithdatafrom
adult patients (14).
GLP-1 response during the OGTT
was not different between Ab
 CDx-type
2 diabetic patients and obese control sub-
jects. Plasma levels of GLP-1 are reported
to be unaltered (19), reduced (20,21), or
elevated (22) in adults with type 2 diabe-
tes.Furthermore,thedurationandthese-
verity of diabetes control and the degree
of obesity were shown to be indepen-
dently associated with GLP-1 responses
(23), potentially accounting for the liter-
ature-reporteddivergentﬁndings.Nosig-
niﬁcant differences in GLP-1 responses
weredetectedinadultswithtype2diabe-
tesofshortduration(3.22.8years)and
with relatively good glycemic control
(A1C 6.8  0.9%) compared with sub-
jects with impaired glucose tolerance and
control subjects (19). Our similar ﬁnd-
ingsofnosigniﬁcantdifferencesinGLP-1
levels between Ab
 and obese control
subjects are most likely related to the
short duration of diabetes (7.3  1.5
months) and well-controlled glycemia
(Table 1). In adults with type 1 diabetes,
GLP-1 responses are reported to be nor-
mal (20) or reduced compared with con-
trol subjects (21). Furthermore, BMI has
been shown to correlate inversely with
GLP-1 (19,23). Among the subset of pa-
tients who had GLP-1 evaluation, the Ab

group had signiﬁcantly lower BMI com-
paredwiththeothertwogroups.Thiscould
explaintheobservedhigherGLP-1levelsin
the former group, which disappeared after
adjusting for BMI differences.
Last but not least, the observation of
signiﬁcantly lower leptin levels in Ab

youths compared with control subjects is
likely due to the severe insulin deﬁciency
(24). We have shown that in newly diag-
nosed patients with type 1 diabetes insu-
lindeﬁciencyisassociatedwithlowleptin
levels and insulin therapy within days
corrects this deﬁciency before any
changes in weight are observed (24).
In conclusion, fasting and OGTT-
derived surrogate measures of insulin
sensitivity and secretion, with the excep-
tion of fasting C-peptide and OGTT C-
peptide AUC/glucose AUC, are not
sufﬁciently sensitive to detect the signiﬁ-
cant differences in insulin sensitivity and
-cell function demonstrated by the
clamp technique between the two groups
of CDx-type 2 diabetic patients. This un-
derscores the importance of using sensi-
tive methods for assessment of -cell
function and insulin sensitivity in patho-
physiologic studies. Although relatively
small sample sizes may be a limitation of
our study, this resonates with the clinical
relevance of our ﬁndings in that the clini-
cian cannot use fasting or OGTT-derived
parameters reliably in distinguishing the
individual Ab
 from the Ab
 patient. As
the presence of autoimmunity implies
progressive decline in -cell function
(25), our ﬁndings also highlight the im-
portance of determining antibody status
in obese pediatric patients with pheno-
typic type 2 diabetes.
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